rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ERAS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Erasca at jefferies healthcare conference: r&d catalyst in focus
      13h agoInvesting.comERASJEF
      Erasca Partners With Bristol Myers Squibb to Evaluate ERAS-0015 Combination Treatment for Pancreatic Cancer
      17h agoYahoo FinanceERASBMY
      Why is Erasca stock sliding today?
      Nov 17Investing.comERAS
      Erasca Stock In Focus As Combination Trial Begins
      Nov 12Yahoo FinanceERAS
      Erasca (ERAS), What Is Driving Attention Around The Stock Today?
      Oct 27Yahoo FinanceERAS
      Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Erasca (ERAS) and Incyte (INCY)

      Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.

      Oct 27The Globe and MailERASINCYMRK
      Bank of America Securities Keeps Their Hold Rating on Erasca (ERAS)

      Tipranks Press Release.

      Oct 20The Globe and MailERAS
      Erasca (ERAS) Stock Looks Above Fair Value After Its 5x Run
      Oct 19Yahoo FinanceERAS
      Erasca, Inc: The Discount RevMed? (NASDAQ:ERAS)

      Erasca targets the KRAS inhibitor market with early cancer data, Fast Track status, and 2027 trials ahead. Click to read this latest analysis of ERAS stock.

      Oct 15Seeking AlphaERASRVMD
      Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower (NASDAQ:ERAS)

      Erasca is a funded RAS-oncology fast follower with ~$1B liquidity. Click for more on ERAS stock.

      Oct 5Seeking AlphaERAS
      FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage

      On August 24, Erasca (NASDAQ:ERAS) announced that the FDA had granted Fast Track Designation to ERAS-0015, its oral pan-RAS molecular glue, for patients with metastatic pancreatic adenocarcinoma. The designation gives Erasca more frequent contact with regulators and, if the drug keeps clearing bars, a shot at accelerated approval, priority review, and rolling review. For a […]

      Sep 4Yahoo FinanceERAS
      Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Erasca (ERAS) and GlaxoSmithKline (GSK)

      Detailed price information for Gsk Plc ADR (GSK-N) from The Globe and Mail including charting and trades.

      Aug 26The Globe and MailERAS
      Erasca receives FDA fast track status for pancreatic cancer drug
      Aug 24Investing.comERAS
      Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma

      Designation follows encouraging Phase 1 activity across multiple tumor types including 2L+ KRAS G12X pancreatic cancer Three potentially...

      Aug 24BarchartERAS

      This is the newest page. Registered accounts read further back.